Global Custom Market Research Reports Provider Company

phone

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017

  • Published Date: 29 Dec 2017
  • Number of Pages: 766
  • Category: Healthcare and Medical
  • Country: Global
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 54, 25, 1, 17 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.

Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct
Table of Contents
Table of Contents 2
Introduction 5
Bile Duct Cancer (Cholangiocarcinoma) - Overview 6
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development 7
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 23
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 37
Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles 71
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 738
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 740
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 741
Appendix 753

List Of Tables


Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Advenchen Laboratories LLC, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca Plc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Co, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corp, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celldex Therapeutics Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CytomX Therapeutics Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Debiopharm International SA, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Co, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Genentech Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Genoscience Pharma, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by H3 Biomedicine Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Hutchison MediPharma Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ignyta Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Immunitor Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Incyte Corp, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ipsen SA, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Leap Therapeutics Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune LLC, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Molecular Templates Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mundipharma International Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana Plc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Oasmia Pharmaceutical AB, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech Holding ASA, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pharma Mar SA, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Plexxikon Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH (Inactive), H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Puma Biotechnology Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Rafael Pharmaceuticals Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by RedHill Biopharma Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Redx Pharma Plc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sirnaomics Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SynCore Biotechnology Co Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Syndax Pharmaceuticals Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SyntheX Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by tella Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Tesaro Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics Inc, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

The global market size of 3D Mobile Devices is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report

The global market size of Air Automobile Horn is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report

The global market size of Andriod Mobile Game Handle is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports